Major Milestone Announced: Jechobio JLM019 Injection Completes First Patient Dosing in Clinical Trial for Advanced Malignant Tumors

Recently, JLM019 Injection — a Class I innovative drug independently developed by Jecho (Tianjin) Biopharmaceutical Co., Ltd. ("Jechobio") — has successfully completed first patient dosing in its clinical trial for advanced malignant tumors at Peking Union Medical College Hospital. This milestone marks the drug’s official entry into the clinical value validation phase. JLM019 Injection is a CD80/PD-1 bispecific Fc fusion protein with a unique dual synergistic mechanism. Built on a precision-targeted design, the agent is poised to address limitations of existing immunotherapies, improve treatment response rates, and delay the development of tumor drug resistance. By significantly enhancing immunotherapeutic efficacy, it aims to deliver new treatment options and survival prospects for patients with advanced solid tumors and lymphoma. Led by Professor Ba Yi and Professor Han Xiaohong from Peking Union Medical College Hospital, the study is primarily designed to evaluate the safety and tolerability of JLM019 Injection. Jechobio remains committed to advancing innovative therapies to tackle unmet clinical needs and drive growth in the biopharmaceutical sector. The company looks forward to partnering with stakeholders across the industry to accelerate the clinical translation of novel treatments and build a shared future for the field.

The release as fetched from its publisher. jechobio.com ↗